{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:23:20Z","timestamp":1761895400298,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.urolonc.2011.11.002","type":"journal-article","created":{"date-parts":[[2011,12,11]],"date-time":"2011-12-11T12:30:46Z","timestamp":1323606646000},"page":"1212-1221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["In vivo and in vitro effects of RAD001 on bladder cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Carmen","family":"Vasconcelos-N\u00f3brega","sequence":"first","affiliation":[]},{"given":"Rosario","family":"Pinto-Leite","sequence":"additional","affiliation":[]},{"given":"Regina","family":"Arantes-Rodrigues","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Brochado","sequence":"additional","affiliation":[]},{"given":"Maria L.","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Palmeira","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Salvador","sequence":"additional","affiliation":[]},{"given":"Catarina I.","family":"Guedes-Teixeira","sequence":"additional","affiliation":[]},{"given":"Aura","family":"Cola\u00e7o","sequence":"additional","affiliation":[]},{"given":"Luis F.","family":"Palomino","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"L\u00facio","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Paula A.","family":"Oliveira","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2011.11.002_bib1","first-page":"225","article-title":"Cancer Statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2011.11.002_bib2","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2008.21.2134","article-title":"Clinical Cancer Advances 2008: Major research advances in cancer treatment, prevention, and screening\u2014a report from the American Society of Clinical Oncology","volume":"27","author":"Winer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2011.11.002_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00345-006-0061-7","article-title":"Radical cystectomy for invasive bladder cancer: Long-term results of a standard procedure","volume":"3","author":"Stein","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2011.11.002_bib4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/carcin\/bgi266","article-title":"Experimental models of human bladder carcinogenesis","volume":"27","author":"Crallan","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2011.11.002_bib5","first-page":"2","article-title":"Experimental bladder carcinogenesis-rodent models","volume":"28","author":"Oliveira","year":"2006","journal-title":"Exp Oncol"},{"key":"10.1016\/j.urolonc.2011.11.002_bib6","first-page":"3221","article-title":"The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN","volume":"29","author":"Oliveira","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2011.11.002_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.urolonc.2009.07.022","article-title":"CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa","volume":"29","author":"Palmeira","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2011.11.002_bib8","first-page":"111","article-title":"Novel agents on the horizon for cancer therapy","volume":"59","author":"Ma","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"3 Suppl","key":"10.1016\/j.urolonc.2011.11.002_bib9","first-page":"7S","article-title":"Sirolimus: Its discovery, biological properties, and mechanism of action","volume":"35","author":"Seghal","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.urolonc.2011.11.002_bib10","first-page":"8451","article-title":"Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian Cells","volume":"63","author":"Edinger","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2011.11.002_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaad.2007.05.021","article-title":"Sirolimus (rapamycin): From the soil of Easter Island to a bright future","volume":"57","author":"Paghdal","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.urolonc.2011.11.002_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"7","author":"Garcia","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2011.11.002_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","article-title":"Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells","volume":"64","author":"Boulay","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2011.11.002_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4161\/cbt.2.3.360","article-title":"Rapamycins: Mechanism of action and cellular resistance","volume":"2","author":"Huang","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.urolonc.2011.11.002_bib15","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2004.02.141","article-title":"The biology and clinical relevance of the PTEN tumor suppressor pathway","volume":"22","author":"Sansal","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl 2S","key":"10.1016\/j.urolonc.2011.11.002_bib16","doi-asserted-by":"crossref","first-page":"500S","DOI":"10.1016\/j.transproceed.2004.01.059","article-title":"Experience with everolimus","volume":"36","author":"Augustine","year":"2004","journal-title":"Transplant P"},{"key":"10.1016\/j.urolonc.2011.11.002_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.urolonc.2011.11.002_bib18","first-page":"479","article-title":"The mammalian target of the rapamycin (mTOR) kinase pathway","volume":"10","author":"Janus","year":"2005","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.urolonc.2011.11.002_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trre.2005.01.001","article-title":"Rapamycin and tumor growth: Mechanism behind its anticancer activity","volume":"19","author":"Koehl","year":"2005","journal-title":"Transplant R"},{"key":"10.1016\/j.urolonc.2011.11.002_bib20","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","article-title":"RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model","volume":"13","author":"Mabuchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.11.002_bib21","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"World Health Organization\/International Society of Urological Pathology Consensus Classification of Urothelial (transitional cell) neoplasms of the urinary bladder","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2011.11.002_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000321905","article-title":"Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines","volume":"86","author":"Videira","year":"2001","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2011.11.002_bib23","first-page":"4805","article-title":"Preclinical evaluation of gemcitabine\/paclitaxel interactions in human bladder cancer lines","volume":"23","author":"Perabo","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2011.11.002_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-9966-28-3","article-title":"Effect of sirolimus on urinary bladder cancer T24 cell line","volume":"28","author":"Pinto-Leite","year":"2009","journal-title":"J Exp Clin Can Res"},{"key":"10.1016\/j.urolonc.2011.11.002_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.urology.2008.09.070","article-title":"Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder bancer","volume":"73","author":"Fechner","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2011.11.002_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jss.2007.03.061","article-title":"Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells","volume":"145","author":"Tang","year":"2008","journal-title":"J Surg Res"},{"key":"10.1016\/j.urolonc.2011.11.002_bib27","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.4161\/cbt.8.24.9987","article-title":"Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer","volume":"8","author":"Mansure","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.urolonc.2011.11.002_bib28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.18632\/oncotarget.188","article-title":"Targeting the PI3K\/Akt\/mTOR pathway\u2014beyond rapalogs","volume":"1","author":"Markman","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2011.11.002_bib29","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1158\/1078-0432.CCR-09-3202","article-title":"Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells","volume":"17","author":"Chiong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.11.002_bib30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1464-410X.2010.09517.x","article-title":"Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: Possible therapeutic implications","volume":"107","author":"Tickoo","year":"2011","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143911004066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143911004066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:01:48Z","timestamp":1761040908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143911004066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1078143911004066"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2011.11.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo and in vitro effects of RAD001 on bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2011.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}